GlassScriptPhysician profile
Sendhil Krishnan
NPI 1376693325
$31,153.31
in general payments reported to CMS, 2019-2025
41 companies · $952 in 2025
The $952 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $8,318 · 2021: $2,324 · 2022: $2,701 · 2023: $3,193 · 2024: $1,211 · 2025: $952.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,056 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,250 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,055.74 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,250.00 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $21,361.00 | 2019-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $1,455.06 | 2020-2025 | |
| Medtronic Vascular, INC. | $1,376.12 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $900.00 | 2019-2020 | |
| Biotronik INC. | $841.90 | 2019-2022 | |
| Amgen INC. | $797.13 | 2019-2025 | Repatha, Prolia, Evenity |
| Abbott Laboratories | $503.26 | 2019-2021 | |
| Abiomed | $435.98 | 2019-2024 | Impella |
| Astrazeneca Pharmaceuticals LP | $343.13 | 2019-2025 | Airsupra, Wainua |
| Merck Sharp & Dohme LLC | $338.58 | 2020-2025 | Verquvo, Capvaxive, Gardasil |
| Impulse Dynamics (USA) INC. | $293.29 | 2022 | |
| Esperion Therapeutics, INC. | $194.57 | 2020-2021 | |
| Edwards Lifesciences Corporation | $187.38 | 2019-2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Currax Pharmaceuticals LLC | $186.12 | 2023-2024 | Contrave, Nexletol, Nexlizet |
| Boehringer Ingelheim Pharmaceuticals, INC. | $171.19 | 2019-2025 | Jardiance |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sendhil Krishnan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.